History101 Posted - 5 minutes ago

$SAVA $LLY just a friendly reminder to shorts...GLTALs!!

techfan20 Posted - 1 hour ago

Mike T discussed his marketing beating Pink ETF today on the Charles Schwab Network and reviewed the largest holdings including $LLY and PureCycle $PCT Short video https://schwabnetwork.com/video/pink-etf-celebrates-3rd-anniversary?cid=SM:Twitter:MOC:Taylor:Organic:2024-10-14

Thinklikethecompany Posted - 4 hours ago

$LLY divi + stock split:-))) https://www.youtube.com/watch?v=2-UQ0-8ktAM

KabraxisX Posted - 5 hours ago

$LLY Wants to touch $1,000.

DefenseMania Posted - 6 hours ago

Small undiscovered AI stock a sleeper $QQQ $SPY $LLY $INTC https://finance.yahoo.com/news/bigbear-ai-awarded-5-production-130000688.html

Northeast14 Posted - 7 hours ago

$LLY Eli Lilly & Co plans to invest £279 million ($364 million) in a new initiative to support UK biotechs along with a study of the impact of its blockbuster drugs for diabetes and obesity on the use of health-care resources. The Indianapolis-based drugmaker’s investment includes as much as £204 million to establish a Lilly Gateway Labs location in the UK, according to an emailed statement Monday, giving early-stage biotechs access to Lilly’s expertise, lab space and potential financial investment. I WONDER IF THIS WILL BE INTO $GENFF

MrChoudhury Posted - 8 hours ago

Guggenheim Adjusts Price Target on Eli Lilly & Co. $LLY to $1,024 From $884, Maintains Buy Rating

theflynews Posted - 8 hours ago

Boeing to cut 10% of workforce, Lundbeck to acquire Longboard: Morning Buzz - $LLY - https://thefly.com/permalinks/entry.php/LLYid3997856

RRCORNER Posted - 8 hours ago

$SHPH started P2 clinical trial for Ropidoxuridine that could revolutionize radiation therapy. Extremely promising. If successful, shares could see very large multiples. Could get serious attention from $SRTS $CELZ $LLY richardacavalli.wixsite.com NEXGEN CANCER RADIATION | Greenplanetmicrocaps

DonCorleone77 Posted - 10 hours ago

$HIMS $LLY $WW FDA to reconsider barring compounded versions of weight loss drug, Reuters says The U.S. Food and Drug Administration said in a court filing on Friday that it agreed to reconsider a decision it made last month to bar drug compounders from selling their own versions of Eli Lilly's (LLY) blockbuster weight loss and diabetes drugs and would now allow compounding pharmacies and facilities to keep providing the drugs while it reviews whether there is a shortage of their active ingredient, reported Reuters on Friday. The decision was in response to a lawsuit brought by a compounding industry group, the Outsourcing Facilities Association, and after the FDA's decision on Friday to reconsider, U.S. District Judge Mark Pittman in Texas put the lawsuit on hold, the report noted. Shares of Hims & Hers (HIMS), which offers compounded weight loss drugs, are up 10% to $20.61 in early Monday trading.

DeepRoots42 Posted - 11 hours ago

$LLY getting closer to earnings, and getting closer to:

JFDI Posted - 11 hours ago

If youre bullish on celh yum and mcd, then yo gotta be bullish on our main girl $LLY

briefingcom Posted - 11 hours ago

$LLY: Eli Lilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241014064629LLY&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

drwooo Posted - 11 hours ago

$LLY $HIMS 💯 THIS 👇 $NVO

jewell69 Posted - 11 hours ago

$LLY to invest $3B in UK obesity research Victoria Fernandez Crossmark Global Investments on Bloomberg NOW 10/14 8:46 am edt: She said go back in $XLV $XLP Let’s get back in consumer staples when $BAC Merrill. 10/8 said: sell $XLP ASAFP

OpenOutcrier Posted - 11 hours ago

$LLY (+0.2% pre) Lilly to Invest $364 Million in UK Biotech, Obesity Research - BBG https://ooc.bz/l/44679

TraderTimes Posted - 12 hours ago

$HIMS rallying, because on October 12, the FDA agreed to review its decision from last month, which had prohibited manufacturers of compounded medications from offering their own versions of $LLY blockbuster weight loss and diabetes drugs. Pharmacies can continue to produce these medications while the FDA investigates whether there is a shortage of the active ingredient Tirzepatide. This decision followed a lawsuit from the Outsourcing Facilities Association (OFA), claiming that Tirzepatide remains scarce. The FDA’s original decision had hindered the sale of cheaper compounded versions of Zepbound and Mounjaro, affecting many patients relying on these more affordable alternatives. Follow for more insights like these

OpenOutcrier Posted - 12 hours ago

$HIMS (+6.7% pre) US FDA to reconsider decision barring compounded versions of $LLY Lilly weight loss drug - Reuters https://ooc.bz/l/44654

peloswing Posted - 12 hours ago

$HIMS $LLY $NVO | US FDA TO RECONSIDER BAN ON COMPOUNDED VERSIONS OF LILLY'S WEIGHT LOSS DRUG

kylevallans Posted - 12 hours ago

$HIMS $LLY $NVO

MrChoudhury Posted - 12 hours ago

$LLY Brilliant Interview with Eli Lilly’s CEO Dave Ricks on All-In podcast https://youtu.be/023exhA9irY?si=foyr4BSFBce2Hqj9 * CC’ing $NVO as their partnership with innovations reflects throughout the interview

Don0071992 Posted - 13 hours ago

$LLY 950 today

DonCorleone77 Posted - 13 hours ago

$LLY Eli Lilly announces one-year histologic mirikizumab data Eli Lilly announced data demonstrating more patients with moderately to severely active Crohn's disease treated with mirikizumab achieved histologic response at Week 52 compared to ustekinumab, regardless of prior biologic experience. VIVID-1 is the first Phase 3 study for any approved or investigational treatment in Crohn's disease to report histologic and combined histologic-endoscopic outcomes that were evaluated using a systematic assessment of five bowel segments and strict definitions consistent with the recently published European Crohn's and Colitis, or ECCO, position statement on mucosal histopathology. These results are being presented as an oral presentation at United European Gastroenterology, or UEG, Week, held in Vienna, Austria from October 12-15. Mirikizumab is an IL23p19 antagonist that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. Inflammation due to the overactivation of the IL-23 pathway plays a critical role in pathogenesis of Crohn's disease, a chronic, inflammatory bowel disease associated with progressive bowel damage, disability and decreased health-related quality of life. In VIVID-1, mirikizumab achieved nominally statistically significant improvements across all histologic and histologic-endoscopic endpoints versus placebo at Weeks 12 and 52, and versus ustekinumab on the following endpoints. A greater number of patients that achieved histologic response were observed with mirikizumab at Week 52 in the overall population. In patients with active histologic disease at baseline and with at least one prior biologic failure, mirikizumab also showed greater histologic response at Week 52 and endoscopic-histologic response at Week 52. The overall safety profile of mirikizumab in patients with moderately to severely active Crohn's disease was consistent with the known safety profile in patients with ulcerative colitis, or UC. The frequency of serious adverse events was greater in placebo than mirikizumab. The most common adverse events were COVID-19, anemia, arthralgia, headache, upper respiratory tract infection, nasopharyngitis and injection site reactions. Lilly has submitted marketing authorization applications for mirikizumab in Crohn's disease around the globe, including in the U.S., Europe, Japan and China. Additional global regulatory submissions are planned. Lilly is committed to finding solutions to elevate care and improve treatment outcomes for people living with inflammatory bowel disease, which includes studying the long-term efficacy and safety of mirikizumab in pediatric patients and adults. Mirikizumab is approved for the treatment of moderately to severely active UC in adults and is marketed as Omvoh. Mirikizumab has additional ongoing trials in UC, including a study in pediatric patients and a study to evaluate the long-term efficacy and safety of mirikizumab in adults. Lilly is continuing to advance the science with an open-label UC trial studying two new endpoints in the assessment of bowel urgency with frequency and deferral time, both of which impact the quality of life for patients.

safeway Posted - 14 hours ago

$ADBE $QQQ $LLY stable way.

Country2busy Posted - 14 hours ago

$LLY

wallstengine Posted - 14 hours ago

$HIMS $LLY $NVO | US FDA TO RECONSIDER BAN ON COMPOUNDED VERSIONS OF LILLY'S WEIGHT LOSS DRUG The FDA has agreed to review its decision to remove tirzepatide, Eli Lilly's active ingredient in Mounjaro and Zepbound, from its shortage list. Compounding pharmacies can continue making tirzepatide versions during the review, after a lawsuit from the Outsourcing Facilities Association challenged the FDA's initial removal. This comes amid high demand for weight loss drugs like tirzepatide and semaglutide, leading to shortages and a growing compounding market.

TheProphetOfProfit Posted - 22 hours ago

$LLY broke out over 1-2 month downtrend resistance on Friday. I expect to see continuation here in the coming days/weeks, and I think it’s likely we’ll see new highs by the end of the year.

FreedomQuestTrader Posted - 1 day ago

10/7-10/11 Weekly Recap: $COIN calls +100%🟢 $COIN calls +60%🟢 $LLY calls +100%🟢 $AMD calls +22%🟢 $AMD Calls +15%🟢 $SMCI calls +7% (Swinging) All given for FREE.

peloswing Posted - 1 day ago

$LLY TOLD UK HEALTH SECRETARY THAT NEW DRUG HAD ‘POTENTIAL TO PREVENT ALZHEIMER’S - FT

HostileCharts Posted - 1 day ago

$IXJ - iShares Global Healthcare ETF Finding support on the pullback, did not get oversold. Pretty clean r/r if you like buying the "NOT A TOP" trades. Top Holdings $LLY ~8% $UNH ~7% $NOVOB ~5% $JNJ ~5% $ABBV ~4%